Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka sverige ab - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 100+25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka sverige ab - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 50+12,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

esteve pharmaceuticals s.a.s. - streptozocin - pulver til koncentrat til infusionsvæske, opløsning - 1 g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - citalopramhydrobromid - filmovertrukne tabletter - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 100+12,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - streptozocin - pulver til koncentrat til infusionsvæske, opløsning - 1 g

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 100+25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - hydrochlorthiazid, losartankalium - filmovertrukne tabletter - 50+12,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medac, gesellschaft für klinische spezialpräparate mbh - methotrexat - injektionsvæske, opløsning i fyldt injektionssprøjte - 50 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.